Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Molecular Partners AG MOLN
$6.70
-$0.02 (-0.24%)
На 18:04, 12 мая 2023
+332.84%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
230764160.00000000
-
week52high
8.00
-
week52low
5.50
-
Revenue
189556000
-
P/E TTM
2
-
Beta
0.61297700
-
EPS
4.10000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 04:00
Описание компании
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Molecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor Conferences
GlobeNewsWire
30 дек 2022 г. в 01:00
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in the 41st annual JP Morgan Healthcare Conference in San Francisco, CA. In addition, members of Molecular Partners management will participate in several upcoming investor events in Switzerland during January 2023.
Molecular Partners AG (MOLN) Q2 2022 Earnings Call Transcript
Seeking Alpha
26 авг 2022 г. в 12:58
Molecular Partners AG (NASDAQ:MOLN ) Q2 2022 Earnings Conference Call August 25, 2022 8:00 AM ET Company Participants Seth Lewis - SVP of IR Patrick Amstutz - CEO Andreas Emmenegger - CFO Conference Call Participants Georgi Yordanov - Cowen and Company Richard Vosser - JPMorgan Daina Graybosch - SVB Securities Jo Walton - Credit Suisse Zoe Karamanoli - RBC Capital Markets Operator Good day, and welcome to the Molecular Partners Second Quarter 2022 Half Year Report. All participants will be in listen-only mode [Operator Instructions].
Molecular Partners to Participate in Upcoming Healthcare Investor Conferences
GlobeNewsWire
11 мая 2022 г. в 01:00
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 11, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that members of its management team will participate in two upcoming investor events. In addition, the Company will publish its Q1 2022 earnings report on May 12, after the close of trading at the NASDAQ exchange.
Why Molecular Partners Shares Are Falling
Benzinga
28 апр 2022 г. в 11:12
Molecular Partners AG (NASDAQ: MOLN) shares are trading lower again Thursday on continued weakness after the company recently said its partner Novartis expects the FDA may require additional clinical data for the Emergency Use Application for ensovibep. Vas Narasimhan, Novartis' CEO, also.
Why Molecular Partners Shares Are Getting Hammered
Benzinga
27 апр 2022 г. в 11:22
Molecular Partners AG (NASDAQ: MOLN) shares are trading lower by 36.52% at $8.38 after the company and its partner Novartis expects the FDA may require additional clinical data for the Emergency Use Application for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. Vas.